Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

SmacN7 enhances the sensitivity of pancreatic cancer cells to tumor necrosis factor-related apoptosis-inducing ligand or gemcitabine.

Zhou W, Shi J, Niu Z, Luo H, Tian H, Gao J, Yu F, Li S.

Oncol Lett. 2013 Jun;5(6):1760-1764. Epub 2013 Apr 3.

3.

Mechanisms of TRAIL and gemcitabine induction of pancreatic cancer cell apoptosis.

Zhao B, Li L, Cui K, Wang CL, Wang AL, Sun ZQ, Zhang B, Zhou WY, Niu ZX, Tian H, Xue Y, Li S.

Asian Pac J Cancer Prev. 2011;12(10):2675-8.

4.
5.

X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells.

Roa WH, Chen H, Fulton D, Gulavita S, Shaw A, Th'ng J, Farr-Jones M, Moore R, Petruk K.

Clin Invest Med. 2003 Oct;26(5):231-42.

PMID:
14596484
6.

Synthetic Smac peptide enhances chemo-sensitivity of bladder cancer cells.

Wang J, Zeng F, Wang L, Zhu Z, Jiang G.

J Huazhong Univ Sci Technolog Med Sci. 2008 Jun;28(3):304-7. doi: 10.1007/s11596-008-0317-0. Epub 2008 Jun 19.

PMID:
18563329
7.

Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.

Karikari CA, Roy I, Tryggestad E, Feldmann G, Pinilla C, Welsh K, Reed JC, Armour EP, Wong J, Herman J, Rakheja D, Maitra A.

Mol Cancer Ther. 2007 Mar;6(3):957-66. Epub 2007 Mar 5.

8.

Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.

Mori T, Doi R, Kida A, Nagai K, Kami K, Ito D, Toyoda E, Kawaguchi Y, Uemoto S.

J Surg Res. 2007 Oct;142(2):281-6. Epub 2007 Jul 19.

PMID:
17640673
9.
10.
11.

Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.

Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR.

Breast Cancer Res Treat. 2013 Jan;137(2):359-71. doi: 10.1007/s10549-012-2352-6. Epub 2012 Dec 7.

PMID:
23225169
12.

Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro.

MacFarlane M, Merrison W, Bratton SB, Cohen GM.

J Biol Chem. 2002 Sep 27;277(39):36611-6. Epub 2002 Jul 16.

14.
16.
18.

AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.

Pieczykolan JS, Kubiński K, Masłyk M, Pawlak SD, Pieczykolan A, Rózga PK, Szymanik M, Gałązka M, Teska-Kamińska M, Żerek B, Bukato K, Poleszak K, Jaworski A, Strożek W, Świder R, Zieliński R.

Invest New Drugs. 2014 Dec;32(6):1155-66. doi: 10.1007/s10637-014-0153-y. Epub 2014 Sep 4.

PMID:
25182378
19.

Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.

Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P.

Oncogene. 2003 May 15;22(19):2869-81.

PMID:
12771938
20.

IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.

Armstrong MJ, Stang MT, Liu Y, Yan J, Pizzoferrato E, Yim JH.

Cancer Biol Ther. 2015;16(7):1029-41. doi: 10.1080/15384047.2015.1046646.

Supplemental Content

Support Center